Compounded Topical Isotretinoin Offers Acne Care Outside iPLEDGE

Isoclear, a compounded topical isotretinoin system from Clear Health, is designed to treat acne outside the requirements of the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS), according to Aaron Farberg, MD, a board-certified dermatologist based in Dallas, Texas who helped develop the treatment.¹

Because Isoclear is applied topically and is not an FDA-approved oral isotretinoin product, Farberg said it falls outside the iPLEDGE framework. The treatment is offered through Clear Health as part of a digital-first skincare plan guided by board-certified dermatologists.

No one is bypassing the iPLEDGE system here. Isoclear is a compounded topical formulation delivered directly to your skin, so it falls entirely outside of the iPLEDGE framework. — Aaron Farberg, MD, FAAD

Oral isotretinoin remains an important treatment for severe, recalcitrant acne, but the enrollment, pregnancy-prevention, and dispensing requirements associated with iPLEDGE can create administrative burdens for patients and prescribers.² Farberg said a topical approach may shift the clinical discussion away from the requirements associated with systemic isotretinoin and toward a localized treatment plan.

Addressing iPLEDGE-Related Treatment Burden

Farberg described prescription pickup windows, pregnancy monitoring, program documentation, and potential treatment interruptions as sources of administrative and emotional friction that may deter some patients from pursuing oral isotretinoin.

“The administrative and emotional friction here that you get with the iPLEDGE program…is a massive deterrent for many patients who genuinely need this gold-standard care,” Farberg said.

The FDA approved modifications to the iPLEDGE REMS on February 9, 2026, intended to reduce burden while maintaining protections against embryo-fetal exposure. The changes include allowing clinician-approved pregnancy testing outside a medical setting during and after treatment, eliminating the waiting period for a repeat pregnancy test after a missed 7-day prescription window, and removing monthly REMS counseling documentation for patients who cannot become pregnant.²³

Farberg positioned Isoclear as an option for patients seeking to avoid iPLEDGE participation altogether rather than as a direct response to those modifications.

For women, it really shifts our clinical conversation away from this highly regulated government program back to a topical discussion, — Aaron Farberg, MD, FAAD

Although Isoclear is not subject to iPLEDGE, the formulation has not undergone FDA review, and pregnancy safety data specific to the compounded system were not presented in the interview.

Localized Delivery and Systemic Exposure

Isoclear is compounded as a customized gel intended for direct application to acne-prone skin. Farberg described the treatment as locally targeted, with limited systemic absorption compared with oral isotretinoin.

“The tolerability differences between topical and oral isotretinoin are real and obvious,” Farberg said. “Because systemic absorption is minimal and it’s targeted locally, we really bypass many of the standard systemic side effects that you would get with oral isotretinoin.”

He cited generalized dryness and musculoskeletal symptoms as potential adverse effects associated with oral isotretinoin that he said would be less likely with a localized topical treatment. He also said Isoclear does not require the routine laboratory monitoring commonly used during oral isotretinoin therapy.

These statements reflect Farberg’s perspective as a physician involved in developing the product. No formulation-specific pharmacokinetic data, adverse-event rates, or comparative safety findings were presented during the interview.

Supporting the Skin Barrier and Treatment Adherence

Farberg said the compounded gel is designed to balance active acne treatment with skin barrier tolerability. He suggested that reducing local irritation may help patients use the treatment more consistently than topical regimens they perceive as harsh.

“This really allows us to maintain this powerful clinical efficacy, the impact on active acne, while also paying attention to the skin barrier and keeping it significantly calmer,” Farberg said.

Clear Health describes Isoclear as a multi-phase system in which compounded formulations may be adjusted over time according to acne activity, post-acne dyspigmentation, skin barrier needs, and treatment response.⁴ The announced regimen may combine topical isotretinoin with ingredients including clindamycin, tranexamic acid, niacinamide, and copper peptide depending on the treatment phase.⁴

Farberg noted that the individual ingredients have previously been used in topical dermatologic formulations.

“All of these ingredients have been studied and utilized in a variety of other topicals,” he said. “They’re already used and studied for these purposes, and we’re just putting them all together in the form of Isoclear.”

Evidence supporting individual ingredients, however, does not establish the safety or efficacy of the combined Isoclear regimen.

Comparing Compounded and Standard Formulations

Farberg compared the distinction between compounded and conventional treatments to choosing between different vehicles traveling to the same destination.

“You have different cars you can take to work. You have a Honda or you have a Ferrari,” Farberg said. “They might both get you there, but the Ferrari feels better, moves quicker. It just overall is better.”

Although the analogy reflects Farberg’s confidence in the compounded approach, no head-to-head clinical studies comparing Isoclear with FDA-approved topical retinoids or oral isotretinoin were presented.

Isoclear adds a compounded option to an acne treatment landscape that already includes FDA-approved topical retinoids, combination therapies, antibiotics, hormonal treatments, and oral isotretinoin. Its place relative to established therapies remains uncertain pending published pharmacokinetic, efficacy, and safety data specific to the complete formulation.

REFERENCES:

1. Farberg A. Isoclear compounded topical isotretinoin. Dermatology Times video interview. July 22, 2026.
2. FDA updates iPLEDGE REMS with new modifications for pregnancy testing and prescription windows. Dermatology Times. Published February 10, 2026. Accessed July 22, 2026. https://www.dermatologytimes.com/view/fda-updates-ipledge-rems-with-new-modifications-for-pregnancy-testing-and-prescription-windows
3. iPLEDGE Risk Evaluation and Mitigation Strategy (REMS). US Food and Drug Administration. Updated February 10, 2026. Accessed July 22, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ipledge-risk-evaluation-and-mitigation-strategy-rems
4. Clear Health launches Isoclear, the first prescription topical isotretinoin system for acne treatment in the US. News release. Business Wire. Published June 17, 2026. Accessed July 22, 2026. https://www.businesswire.com/news/home/20260617471674/en/Clear-Health-Launches-Isoclear-the-First-Prescription-Topical-Isotretinoin-System-for-Acne-Treatment-in-the-U.S.